Home » AbbVie’s Humira Gains Tenth Indication in U.S.
AbbVie’s Humira Gains Tenth Indication in U.S.
AbbVie’s blockbuster therapy Humira has gone double digits with FDA-approved indications after the agency just approved the drug to treat non-infectious intermediate-, posterior- and pan-uveitis.
The approval marks Humira’s tenth indication in the U.S. for immune-mediated diseases, AbbVie says. It was first approved back in 2002.
Humira also picked up EU approval in June to treat non-infectious intermediate-, posterior- and pan-uveitis.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May